Short answer
CARLSMED, INC. (CARL) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
CARLSMED, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and investor-relevant metrics available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $21.6M, up 65% year over year, signaling strong adoption of Carlsmed’s AI-enabled spine platform
- Full-year revenue guidance raised to $78M-$80M from $74M-$78M, implying over 56% midpoint growth
- Gross margin improved to 77.3% from 75.9%, supporting the company’s capital-light profitability strategy
- GAAP net loss widened to $12.2M from $8.5M as operating expenses reached $29.4M, including $2.8M of transition and legal costs
- Cash, investments and securities totaled $80.3M, while adjusted EBITDA improved to negative $7.3M from negative $8.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CARLSMED, INC. 8-K filings
Get the next CARL 8-K as it lands
Follow CARL for push alerts, or ask the research agent what this filing means.